Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously irradiated head and neck cancer
- 1 October 2013
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 124 (7) , 1579-1584
Abstract
Objectives/Hypothesis: Locoregional recurrence remains the primary failure pattern following salvage surgery for previously irradiated head and neck cancer; randomized trials have suggested a complimentary role for adjuvant chemotherapy and conventional reirradiation at the expense of significant increases in toxicity. We aimed to identify if stereotactic body radiotherapy (SBRT) ± cetuximab improves tumor control while reducing treatment‐related toxicity following salvage surgery.Study Design: Retrospective review (2005–2011) of 28 patients with high‐risk features (positive surgical margins or extranodal extension) following macroscopic complete (R0/R1) salvage surgery treated with adjuvant SBRT ± cetuximab.Methods: SBRT consisted of 40 to 44 Gy in five fractions over 1 to 2 weeks with concurrent cetuximab (n = 7) administered at 400 mg/m2 day −7 + 250 mg/m2 days 0 and +8. Toxicity was physician recorded, and University of Washington Quality of Life Revised surveys were prospectively collected.Results: All patients received prior radiotherapy (median, 70 Gy; range, 54–99 Gy) with a median reirradiation interval of 25 months (range, 6–156 months). At a median follow‐up of 14 months (range, 2–69 months), the 1‐year locoregional control, distant control, disease‐free survival, and overall survival were 51%, 90%, 49%, and 64%, respectively. Rates of acute and late severe (≥grade 3) toxicity were low at 0% and 8%, respectively. At a median follow‐up survey time of 6 months, 56% of patients reported improved/stable overall quality‐of‐life scores.Conclusions: Adjuvant SBRT ± cetuximab following salvage surgery is well tolerated with acceptable oncologic outcomes and little toxicity. Future prospective trials should evaluate adjuvant SBRT ± cetuximab versus a wait‐and‐see approach for recurrent head and neck cancers with high‐risk features following salvage surgery.Level of Evidence: 4 Laryngoscope, 124:1579–1584, 2014Keywords
This publication has 21 references indexed in Scilit:
- Reirradiation for recurrent head and neck cancerExpert Review of Anticancer Therapy, 2012
- ACR Appropriateness Criteria® Retreatment of Recurrent Head and Neck Cancer After Prior Definitive RadiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynxCancer, 2009
- Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck CarcinomaJournal of Clinical Oncology, 2008
- Results of postoperative reirradiation for recurrent or second primary head and neck carcinomaCancer, 2006
- Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experienceAnnals of Oncology, 2004
- Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck CancerNew England Journal of Medicine, 2004
- Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Salvage Surgery for Patients With Recurrent Squamous Cell Carcinoma of the Upper Aerodigestive Tract: When Do the Ends Justify the Means?The Laryngoscope, 2000